Highest-materiality recent filing
Establishment Labs Q2 revenue $67.5M (+31.7% YoY); raises FY guidance to $269-271M
Revenue of $67.5M, up 31.7% YoY; US sales $24.7M, up 26% from Q1 2026.
Establishment Labs appoints Taylor Harris to Board of Directors
Taylor Harris appointed to Board effective June 24, 2026; will serve on Audit and Nominating & Governance Committees.
Seven directors elected with votes ranging from 17.3M to 20.0M; broker non-votes 3.1M.
Revenue of $59.9M, up 44.7% YoY; US Motiva sales $19.6M (vs $6.2M Q1 2025).
Establishment Labs enters up to $300M credit facility with Oaktree; repays ~$259M existing debt
Tranche E Term Loan of $265M drawn April 30, 2026; optional Tranche F up to $35M.
Establishment Labs Q4 rev $64.6M (+45% YoY); guides 2026 rev $264-266M
Full year 2025 revenue $211.1M (+27.2% YoY); Q4 net loss $3.9M vs $18.7M loss a year ago.
Presentation at J.P. Morgan conference; no financial updates disclosed
Furnished presentation materials for J.P. Morgan Healthcare Conference on Jan 14, 2026.
Establishment Labs expects Q4 revenue $64M-$65M; FY 2025 up 27% YoY
Q4 2025 revenue expected $64.0M-$65.0M, including $17.0M-$17.5M from Motiva US sales.
Establishment Labs Q3 revenue $53.8M (+33.8% YoY), positive Adj. EBITDA, raises FY guidance
Revenue $53.8M, up 33.8% YoY; US Motiva sales $11.9M.
Establishment Labs amends credit agreement, draws $25M Tranche D term loans
Fourth Amendment allows immediate availability of $25M Tranche D Term Loans, waiving revenue milestone.
Establishment Labs Q2 revenue $51.3M (+16% YoY); raises FY2025 guidance to $208-212M
Revenue $51.3M, up 16.3% YoY; US Motiva sales $10.3M.
Motiva USA update: >1,000 surgeons, Q2 sales guide $9.5-10M, reconstruction filing Q4 2025
Over 1,000 surgeons now offer Motiva implants in the United States.
Shareholders re-elect all director nominees; Bryan Slotkin receives 92% for
All four director nominees elected: Chacón Quirós, Custin, Lewin, Schutter each received >21.4M for; Slotkin 19.9M for, 1.7M against.
Establishment Labs replaces auditor Marcum with CBIZ after acquisition of attest business
Marcum resigned May 20, 2025; Audit Committee appointed CBIZ same day for FY 2025.
Establishment Labs appoints Peter Caldini as permanent CEO, effective May 7, 2025
Caldini had served as interim CEO since March 1, 2025, following founder Juan José Chacón-Quirós's retirement.
Establishment Labs Q1 revenue $41.4M, net loss $20.7M; appoints Peter Caldini CEO
Q1 revenue $41.4M (up from $37.2M YoY); net loss $20.7M vs $16.2M loss in prior year.
Establishment Labs reports preliminary Q1 revenue $41.4M, reiterates 2025 guidance $205-210M
Preliminary Q1 2025 revenue ~$41.4M, including ~$6.2M US Motiva sales.
Establishment Labs Q4 revenue $44.5M; reaffirms 2025 guidance of $205-210M
Q4 revenue $44.5M (+41% YoY); gross margin 68.5% (up from 65.2%).
Establishment Labs guides 2025 revenue $205M-$210M, positive adjusted EBITDA in 2025
2025 revenue guidance of $205M-$210M ($170M-$175M international, $35M US).
Founder CEO Chacón-Quirós to retire March 1; 2024 revenue guidance $166M-$166.5M
CEO Juan José Chacón-Quirós retires effective March 1, 2025; stays on board and as advisor.
Establishment Labs extends Tranche D loan commitment to Dec 2025 and raises ~$49.8M in equity
Amended credit agreement: Tranche D term loan commitment termination date extended to Dec 31, 2025 from June 30, 2025.
Q3 revenue $40.2M vs $38.5M YoY; net loss $16.7M vs $29.3M loss YoY; adjusted EBITDA loss $7.0M vs $16.3M loss.
Offering of 765,696 common shares at $45.71/share and pre-funded warrants for 328,161 shares; total gross proceeds ~$50M.
FDA approves Motiva SmoothSilk implants for breast augmentation; first new PMA since 2013
FDA approval for Motiva SmoothSilk Ergonomix and Round implants in primary and revision breast augmentation.
Appoints Fillipo 'Peter' Caldini as President; base salary $415K, $1M equity grant
Appointed Fillipo 'Peter' Caldini as President effective August 20, 2024, reporting to CEO.
Establishment Labs Q2 revenue $44.1M, loss narrows; FDA PMA inspection completed
Q2 revenue $44.1M vs $48.6M YoY; gross margin improved to 65.6% from 62.3%.
FDA PMA preapproval inspection of Establishment Labs' Motiva Implant facility rescheduled to July 22
FDA will begin PMA preapproval inspection of Motiva Implants manufacturing facility on July 22, 2024.
FDA deems Establishment Labs' Motiva Implants PMA approvable pending facility inspection
FDA CDRH completed PMA review for Motiva Implants; says PMA is approvable subject to acceptable manufacturing facility inspection.
Establishment Labs shareholders elect directors, approve say-on-pay, ratify auditor
Ann Custin received 18,049,023 votes for, 1,659,450 against; Bryan Slotkin 18,175,945 for, 1,532,799 against.
Q1 2024 revenue $37.2M (down 20% YoY from $46.5M); net loss $16.2M vs $11.9M loss in Q1 2023.
FDA schedules PMA preapproval inspection of Establishment Labs' Motiva Implants facility in Q2 2024
FDA schedules PMA preapproval inspection of Motiva Implants manufacturing facility for Q2 2024.
Establishment Labs Q4 revenue falls 28% YoY to $31.6M; guides 2024 rev up 5-11% to $174-184M
Q4 revenue $31.6M vs $43.8M prior year; net loss from operations $22.1M vs $13.2M.
Establishment Labs amends credit agreement; extends Tranche C/D deadlines, raises rate to 10%
Commitment termination dates extended: Tranche C to Dec 31, 2024 (from Mar 31, 2024); Tranche D to Jun 30, 2025 (from Dec 31, 2024).
Prospectus supplement covers resale of up to 2,000,000 common shares, including shares issuable upon exercise of pre-funded warrants.
Establishment Labs raises $50M via private placement; Q4 rev. $31.4-$31.8M in-line
Gross proceeds of $50M from sale of 2M common shares/pre-funded warrants at $25.00 per share.
COO Paul D. Rodio departs; CEO assumes operating officer duties
Paul D. Rodio, COO, departed Establishment Labs on Dec 8, 2023.
Revenue $38.5M (+0.8% YoY); net loss $29.3M vs $18.6M; operating loss $21.0M vs $10.5M.
Establishment Labs reports record Q2 revenue of $48.6M, up 18% YoY; net loss narrows to $16.7M
Q2 2023 revenue of $48.6M (+18% YoY) sets new quarterly record; gross margin 62.3% vs 66.7% a year ago.
Establishment Labs shareholders approve board declassification and remove supermajority votes
Board declassification over three years: directors elected from 2024 onward serve one-year terms, complete by 2026.
Establishment Labs Q1 revenue $46.5M (+21% YoY), net loss widens to $11.9M
Revenue $46.5M, record quarterly, up 21.0% YoY; currency-adjusted growth 22.9%.
Establishment Labs raises ~$84.1M in public offering of 1.1M shares at $71.50/share
Underwriting agreement for 1,100,000 common shares at $67.21 per share to underwriters; public price $71.50.
Establishment Labs Q1 2023 preliminary revenue ~$46.5M, up 21% YoY
Revenue expected ~$46.5M, compared to $38.5M in Q1 2022, a 21% YoY increase.
Establishment Labs reports 3-year Motiva IDE study data; capsular contracture rate 0.5%
3-year follow-up on 451 primary augmentation patients; compliance 92.4%.
Submitted fourth and final module to U.S. FDA for premarket approval of Motiva Implants in the U.S.
Notified FDA it is ready to submit Module 4 of pre-market approval for Motiva Implants in the U.S.
Establishment Labs Q4 revenue $43.3-44.3M (+23-25% YoY); FY22 revenue $161.2-162.2M (+27-28% YoY)
Q4 2022 preliminary revenue $43.3-44.3M, up 23-25% YoY (27-29% constant currency).
Establishment Labs appoints Paul D. Rodio as COO, effective Dec 1, 2022
Appointed Paul D. Rodio as COO effective Dec 1, 2022; prior roles at Cardinal Health, Medtronic, and Covidien.
Establishment Labs Q3 revenue $38.2M (+31.7% YoY); tightens 2022 guidance to $158-162M
Q3 revenue $38.2M, up 31.7% YoY (37.7% constant currency); net loss $10.5M vs $9.0M in Q3 2021.
Establishment Labs extends option exercise period for departing Head of Global Operations
Pratip Dastidar departed as Head of Global Operations as of Aug 19, 2022, previously announced.
Establishment Labs loses Head of Global Operations; appoints new GC & CCO
Pratip Dastidar, Head of Global Operations, departs Aug 19, 2022; eligible for severance if he signs general release.
appointed the Company’s interim Chief Executive Officer Fillipo “Peter” Caldini to serve as Chief Executive Officer, effective May 7, 2025.
The Board also appointed Mr. Caldini as a Class II director of the Company, effective May 24, 2025.
Fillipo “Peter” Caldini, the Company’s current President, will serve as Interim CEO as of March 1, 2025.
Juan José Chacón-Quirós, the Company’s Chief Executive Officer, has provided notice of his decision to retire from his position as Chief Executive Officer, effective on March 1, 2025.
On August 20, 2024, the Board of Directors of Establishment Labs Holdings Inc. (the “Company”) appointed Fillipo “Peter” Caldini to the position of President of the Company effective immediately (the “Start Date”).
On December 8, 2023, Paul D. Rodio, the Company’s Chief Operating Officer, departed from Establishment Labs Holdings Inc.
The Board of Directors of Establishment Labs Holdings Inc. (the “Company”) has appointed Paul D. Rodio to the position of Chief Operating Officer of the Company.
On August 19, 2022, Pratip Dastidar, the Company’s Head of Global Operations, will depart from Establishment Labs Holdings Inc.
On March 1, 2022, Lisa Gersh notified Establishment Labs Holdings Inc. (the “Company”) that she will resign as a member of the Company's Board of Directors, effective March 31, 2022.
On December 8, 2021, the Board of Directors (the “Board”) of Establishment Labs Holdings Inc. (the “Company”) appointed Raj Denhoy as the Company’s permanent Chief Financial Officer, effective immediately.
On December 8, 2021, the Board of Directors (the “Board”) of Establishment Labs Holdings Inc. (the “Company”) appointed Leslie Gillin to the Board as a Class II director, effective immediately
On July 13, 2021, the Board of Directors (the “Board”) of Establishment Labs Holdings Inc. (the “Company”) appointed Ms. Ann Custin and Mr. Bryan Slotkin to the Board, effective immediately.
Max materiality 0.85 · Median 0.70 · Most common event earnings